IP Library Granted Patent US 8,957,196
Granted Patent B2
US 8,957,196 · App. 12/444,567 · Granted Feb 17, 2015

Vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same

Inventors: In Young Choi (Youngin-si, KR); Chang Hwan Kim (Gyeonggi-do, KR); Hyun Ji Lee (Seoul, KR); Seong Hee Park (Seoul, KR); Se Chang Kwon (Seoul, KR); Gwan Sun Lee (Seoul, KR)
Assignee: Hanmi Science Co., Ltd.
C12N9/003C12N15/85C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,196
App. No.
12/444,567
Granted
Feb 17, 2015
Kind
B2
Abstract

Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.

Claims (26)

1. An isolated inducible high-expression cassette comprising the nucleotide sequence of SEQ ID NO. 10, wherein one or more CCGCCC repeat sequences are removed from the GC-rich region of positions 8 to 67 of SEQ ID NO. 10.

2. The inducible high-expression cassette according to claim 1 , wherein the GC-rich region contains one or zero CCGCCC repeat sequences.

3. An inducible high-expression cassette comprising any one nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID Nos. 7, 8, and 9.

4. An expression vector comprising the inducible high-expression cassette of claim 1 .

5. The expression vector according to claim 4 , which further comprises a gene encoding a physiologically active polypeptide.

6. The expression vector according to claim 5 , wherein the physiologically active polypeptide is human erythropoietin.

7. An expression vector comprising any one nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID Nos. 1, 2, and 3.

8. An expression vector comprising the nucleotide sequence of SEQ ID No. 5 or 6.

9. A cell line transformed with the expression vector of claim 8 .

10. The cell line according to claim 9 , which has accession number KCTC10991BP or KCTC10992BP.

11. A cell line transformed with the expression vector of claim 5 .

12. The cell line according to claim 11 , which is a CHO cell line.

13. The cell line according to claim 12 , wherein the CHO cell line is deficient in a dihydrofolate reductase gene.

14. The cell line according to claim 12 , which has accession number KCTC10993BP, KCTC10994BP or KCTC10995BP.

15. A method of producing a recombinant protein comprising the steps of:

(a) transforming an animal cell line with an expression vector including the isolated inducible high-expression cassette of claim 1 and a gene encoding the recombinant protein;

(b) culturing the transformed animal cell line in presence of a dihydrofolate reductase inhibitor; and

(c) isolating the recombinant protein.

16. The method according to claim 15 , wherein the recombinant protein is human erythropoietin.

17. The method according to claim 16 , which further comprises purifying erythropoietin having a high sialic acid content.

18. The method according to claim 15 , wherein the animal cell line of step (a) is a dihydrofolate reductase-deficient CHO cell line.

19. The method according to claim 15 , wherein the transformed animal cell line of step (b) has accession number KCTC10993BP, KCTC10994BP or KCTC10995BP.

20. A method of producing a recombinant protein comprising the steps of:

(a) transforming an animal cell line with an expression vector including the isolated inducible high-expression cassette of claim 3 and a gene encoding the recombinant protein;

(b) culturing the transformed animal cell line in presence of a dihydrofolate reductase inhibitor to produce the recombinant protein; and

(c) isolating the recombinant protein.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2011
From: HANMI PHARMACEUTICAL CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025588/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2009
From: CHOI, IN YOUNG; KIM, CHANG HWAN; LEE, HYUN JI; PARK, SEONG HEE; KWON, SE CHANG; LEE, GWAN SUN
To: HANMI PHARMACEUTICAL CO., LTD.
Reel/Frame 023563/0426 →
Priority Claims (1)
KR 10-2006-0100507 · Oct 16, 2006 · national
Continuity (1)
Related Publication 20100120089A1 · May 13, 2010